SWE
Toggle navigation
English
Svenska
About Us
The Company
Board & Management
Scientific Advisory Board
Scientific Publications
Events & Mediawatch
Careers
Contact Us
Expanded Access Policy
Diabetes
Products
Manufacturing
Clinical Trials
Investors
Investor Relations
CEO Comments
Corporate Governance
Press Releases
Financial Reports
Financial Calendar
Skip Navigation Links
Home
»
Investors
»
Press Releases
Diamyd Medical’s financial year comprises 1 September – 31 August.
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Data pager
Data pager
1
2
3
Show:
PageSizeComboBox
select
10
20
50
100
150
3 pages
Press Releases
Data pager
Data pager
1
2
3
Show:
PageSizeComboBox
select
10
20
50
100
150
3 pages
9/9/2024
Diamyd Medical to pursue accelerated approval pathway for Type 1 Diabetes precision medicine
9/2/2024
The exercise period for Diamyd Medical's warrants of series TO 3 begins today
7/30/2024
Diamyd Medical Announces Positive Interim Analysis Results for Phase 3 Trial in Type 1 Diabetes
7/23/2024
Diamyd Medical receives positive feedback from FDA on potential Accelerated Approval for Diamyd
®
in Type 1 Diabetes
7/18/2024
Diamyd Medical receives second U.S. FDA Fast Track designation for Diamyd
®
- for the prevention of Type 1 Diabetes
6/26/2024
Quarterly Report III 23/24
5/16/2024
Diamyd Medical updates on the registrational Phase 3 trial; upcoming interim analysis and enrollment
4/18/2024
Diamyd Medical announces final outcome in the company’s rights issue
4/16/2024
Diamyd Medical announces preliminary outcome in the company’s rights issue
4/12/2024
Recruitment milestone reached in Diamyd
®
Phase 3 trial
Order GAD for preclinical research
ORDER
©
Privacy Policy
|
Cookie Policy
|
Expanded Access Policy
Share This Page
select
Facebook
Twitter
LinkedIn
Google Plus
Pinterest
Tumblr
StumbleUpon
Blogger
MySpace
Digg
Reddit
Email
GAD PRODUCTS
Order GAD for preclinical research